SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 270.25 |
| Enterprise Value ($M) | 258.77 |
| Book Value ($M) | 15.98 |
| Book Value / Share | 0.62 |
| Price / Book | 16.91 |
| NCAV ($M) | 9.89 |
| NCAV / Share | 0.38 |
| Price / NCAV | 27.33 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.22 |
| Return on Assets (ROA) | -0.17 |
| Return on Equity (ROE) | -0.32 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.41 |
| Current Ratio | 1.51 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 29.75 |
| Assets | 35.84 |
| Liabilities | 19.86 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Opaleye Management Inc. | 10.34 | 5.85 | |
| 13D/A | Imprimis Pharmaceuticals, Inc. | 0.00 | -100.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 31,848 | 535,169 | 5.95 | |
| 17,647 | 201,133 | 8.77 | |
| 58,389 | 635,880 | 9.18 | |
| 32,478 | 271,720 | 11.95 | |
| 79,454 | 572,871 | 13.87 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| EOLS – Evolus, Inc. | ESPR – Esperion Therapeutics, Inc. |
| ETNB – 89bio, Inc. | FATE – Fate Therapeutics, Inc. |
| FBLG – FibroBiologics, Inc. |
Financial data and stock pages provided by
Fintel.io